Shareholder Update March 2011
In this issue:
› Enrolment completed for Phase2 study of VivaGel® for treatment of BV
› Strengthening shareholderbase – new domestic and European investors
› Broad appeal of SPL’sdendrimer technology platform – agrochemicals and drug delivery
› Starpharma’s performance vs the market
Download: Shareholder Update: March 2011 ( pdf file, 530kb)
Completes Enrolment for Phase 2 Study of VivaGel for Treatment of BV
Starpharma today announced it had completed enrolment and all patient follow-up visits in its phase 2 study of VivaGel® for the treatment of bacterial vaginosis (BV).
This study investigated the effectiveness of VivaGel® administered once daily for seven days in the treatment of BV and enrolled 132 participants in the US. Data is now being processed and results will be available in the second quarter of this year.
Starpharma presents at ASX Emerging Growth Conference, London
Starpharma is today presenting at the ASX Emerging Growth conference in London.
More than 150 institutional fund managers are confirmed for the event. Starpharma is one of 18 companies participating in this invitation only event, and one of only two healthcare companies. Mesoblast is the other.
Presentation: SPL presents at ASX Emerging Growth Conference ( pdf file, 2MB)
Starpharma to expand agricultural program through $250,000 funding
Starpharma has been awarded $250,000 funding to enhance agrochemicals using its Priostar® dendrimers. The funding as part of the Victorian Government’s Small Technologies Industry Uptake Program (STIUP), will allow Starpharma to expand its Melbourne-based agricultural programs, further enhancing the commercial prospects of promising candidates.